CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 32 enrolled
Drug / intervention
Rucaparib +1 moredrug
Likely dose
Rucaparib 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03639935
NCT03639935Phase 2Completed
CompareCT.gov

Phase II Multi-Center Study of PARP Inhibitor Rucaparib in Combination With Anti-PD-1 Antibody Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy

University of Michigan Rogel Cancer Center·interventional·Posted Aug 21, 2018·Updated Jun 3, 2025

In Brief

A Phase 2 clinical trial evaluating Rucaparib and Nivolumab for Biliary Tract Cancer. Completed, enrolled 32 participants across 3 sites.

Detailed Summary

Investigators hypothesize that following first-line platinum based chemotherapy, rucaparib in combination with nivolumab, will improve progression-free survival and overall survival in BTC patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBiliary Tract Cancer
CountriesUnited States
CollaboratorsDana-Farber Cancer Institute, Vanderbilt University Medical Center

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedAug 21, 2018
Enrollment StartMar 28, 2019
Primary CompletionFeb 7, 2023
Study CompletionApr 30, 2024
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 7.9 years ago

Interventions

Rucaparibdrug

Rucaparib 600 mg PO BID days 1-28

Nivolumabdrug

Nivolumab 240 mg IV days 1 and 15